Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2012 1
2013 1
2014 2
2015 1
2016 2
2017 4
2018 2
2020 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Hill R, Madureira PA, Ferreira B, Baptista I, Machado S, Colaҫo L, Dos Santos M, Liu N, Dopazo A, Ugurel S, Adrienn A, Kiss-Toth E, Isbilen M, Gure AO, Link W. Hill R, et al. Among authors: liu n. Nat Commun. 2023 Jul 19;14(1):4341. doi: 10.1038/s41467-023-40050-1. Nat Commun. 2023. PMID: 37468494 Free PMC article. No abstract available.
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses.
Heller S, Glaeske S, Gluske K, Paul J, Böhme A, Janzer A, Roider HG, Montebaur A, Nicke B, Lesche R, von Ahsen O, Politz O, Liu N, Gorjánácz M. Heller S, et al. Among authors: liu n. Clin Exp Med. 2023 Dec;23(8):5445-5461. doi: 10.1007/s10238-023-01227-6. Epub 2023 Nov 8. Clin Exp Med. 2023. PMID: 37935952 Free PMC article.
Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
Huang D, Song TL, Nairismägi ML, Laurensia Y, Pang WL, Zhe DCM, Wong EKY, Wijaya GG, Tan J, Tan SH, Lim JQ, Chia BKH, Chan JY, Tang TPL, Somasundaram N, Cheng CL, Politz O, Liu N, Lim ST, Ong CK. Huang D, et al. Among authors: liu n. Br J Haematol. 2020 May;189(4):731-744. doi: 10.1111/bjh.16435. Epub 2020 Jan 31. Br J Haematol. 2020. PMID: 32004387 Free PMC article.
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Tarantelli C, Lange M, Gaudio E, Cascione L, Spriano F, Kwee I, Arribas AJ, Rinaldi A, Jourdan T, Berthold M, Sturz A, Sperl C, Margheriti F, Scalise L, Gritti G, Rossi D, Stathis A, Liu N, Zucca E, Politz O, Bertoni F. Tarantelli C, et al. Among authors: liu n. Blood Adv. 2020 Mar 10;4(5):819-829. doi: 10.1182/bloodadvances.2019000844. Blood Adv. 2020. PMID: 32126142 Free PMC article.
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
Scott WJ, Hentemann MF, Rowley RB, Bull CO, Jenkins S, Bullion AM, Johnson J, Redman A, Robbins AH, Esler W, Fracasso RP, Garrison T, Hamilton M, Michels M, Wood JE, Wilkie DP, Xiao H, Levy J, Stasik E, Liu N, Schaefer M, Brands M, Lefranc J. Scott WJ, et al. Among authors: liu n. ChemMedChem. 2016 Jul 19;11(14):1517-30. doi: 10.1002/cmdc.201600148. Epub 2016 Jun 16. ChemMedChem. 2016. PMID: 27310202 Free PMC article.
18 results